Advertisement

U.S. Markets open in 7 hrs 2 mins

S&P Futures
3,902.00
+4.25(+0.11%)
Dow Futures
31,241.00
+39.00(+0.12%)
Nasdaq Futures
11,838.00
-40.25(-0.34%)
Russell 2000 Futures
1,771.50
-3.40(-0.19%)
Crude Oil
110.35
+0.46(+0.42%)
Gold
1,845.10
+3.90(+0.21%)

Advertisement

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

3.3500

-0.0500

(-1.47%)

At close: 04:00PM EDT

Advertisement

Loading interactive chart...

Simply Wall St.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Just Slashed This Year's Revenue Estimates By 20%
Market forces rained on the parade of Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders today, when the analysts...
Zacks
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Business Wire
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
BEDFORD, Mass., May 09, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended March 31, 2022, and provided updates on its ophthalmology pipeline.